<DOC>
	<DOCNO>NCT00794261</DOCNO>
	<brief_summary>The purpose study evaluate efficacy tolerance single administration Pegfilgrastim patient lymphoma myeloma receive high-dose chemotherapy autologous peripheral stem cell support , estimate cost incur . Eligible patient randomize . The estimated inclusion period approximately 18 month . The duration research 22 month . The maximum duration participation patient 3 month . The number patient require multicentric prospective study 150 ( 13 participate center ) . This phase II , control , randomize , non comparative open-label multicentric study .</brief_summary>
	<brief_title>Stem Cell Mobilization With Pegfilgrastim Lymphoma Myeloma</brief_title>
	<detailed_description>High-dose chemotherapy autologous peripheral stem cell ( PSC ) transplantation standard consolidation treatment initial management patient myeloma treat high-dose Melphalan , patient certain lymphomas chemosensitive relapse Hodgkin 's lymphoma ( HL ) malignant non Hodgkin 's lymphoma ( MNHL ) . This procedure associate prolong neutropenia considerable morbidity . Many randomized trial test post-graft administration granulocyte growth factor ( granulocyte colony stimulate Factor : G-CSF ) granulocyte-monocyte growth factor ( granulocyte macrophage colony stimulate Factor : GM-CSF ) . All show reduction neutropenia shorter hospital stay G-CSF GM-CSF treatment . Different guideline recommend use growth factor autologous stem cell transplantation . The effectiveness growth factor treatment would identical , whether give immediately PSC transplantation delay D5 D7 . Pegfilgrastim growth factor result modification Filgrastim addition polyethylene glycol ( PEG ) moiety , increase half-life decrease renal clearance . Thus , one injection equivalent several Filgrastim injection . Studies Pegfilgrastim Filgrastim efficacy duration chemotherapy-induced neutropenia patient breast cancer non-small cell lung cancer LMNH produce equivalent result . In haematology , Pegfilgrastim use PSC mobilization . Six study evaluate efficacy Pegfilgrastim compare G-CSF autologous hematopoietic PSC transplantation patient myeloma lymphomas show equivalent result . A superiority Pegfilgrastim G-CSF even report ( though one randomize small-scale study ) . A randomized phase II study evaluate Pegfilgrastim efficacy tolerance lymphoma myeloma patient receive PSC transplantation appear necessary confirm refute potential clinical interest drug . On day autologous PSC transplantation ( D0 ) patient randomly assign receive one treatment strategy . NB : Patients receive support care , antibiotic treatment transfusion procedure specific participate centre . They followed-up accord recommendation management type patient . No additional examination plan .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Male female patient age ≥ 18 year Patients histologically confirm lymphoma myeloma Treatment highdose chemotherapy inclusion Intensification high dose Melphalan patient myeloma Whatever condition regimen , except TBI patient 1st relapse Hodgkin 's lymphoma MNHL NB : Patients receive two intensification course eligible 100 day course . Autologous PSC transplantation time inclusion Reinjection ≥ 2.106 CD34/kg Patients hospitalize investigator center throughout procedure recovery aplasia ( PNN &gt; 0.5 G/L ) Mandatory affiliation health insurance system Patients able understand , read write French Signed , write informed consent TBI conditioning Severe intolerance growth factor study , hypersensitivity one component Immunosuppressive syndrome Pregnant lactate woman Difficult followup Documented history cognitive psychiatric disorder Participation consideration participation another biomedical study followup period present trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>lymphoma</keyword>
	<keyword>high-dose chemotherapy</keyword>
	<keyword>PSC infusion , autologous</keyword>
	<keyword>neutropenia</keyword>
	<keyword>thrombocytopenia</keyword>
	<keyword>hospital stay</keyword>
	<keyword>infection</keyword>
	<keyword>Autologous PSC transplantation patient lymphoma myeloma treat high-dose chemotherapy</keyword>
</DOC>